Literature DB >> 22115786

Second generation of pseudotype-based serum neutralization assay for Nipah virus antibodies: sensitive and high-throughput analysis utilizing secreted alkaline phosphatase.

Yoshihiro Kaku1, Akira Noguchi, Glenn A Marsh, Jennifer A Barr, Akiko Okutani, Kozue Hotta, Boldbaatar Bazartseren, Shuetsu Fukushi, Christopher C Broder, Akio Yamada, Satoshi Inoue, Lin-Fa Wang.   

Abstract

Nipah virus (NiV), Paramyxoviridae, Henipavirus, is classified as a biosafety level (BSL) 4 pathogen, along with the closely related Hendra virus (HeV). A novel serum neutralization test was developed for measuring NiV neutralizing antibodies under BSL2 conditions using a recombinant vesicular stomatitis virus (VSV) expressing secreted alkaline phosphatase (SEAP) and pseudotyped with NiV F/G proteins (VSV-NiV-SEAP). A unique characteristic of this novel assay is the ability to obtain neutralization titers by measuring SEAP activity in supernatant using a common ELISA plate reader. This confers a remarkable advantage over the first generation of NiV-pseudotypes expressing green fluorescent protein or luciferase, which require expensive and specific measuring equipment. Using panels of NiV- and HeV-specific sera from various species, the VSV-NiV-SEAP assay demonstrated neutralizing antibody status (positive/negative) consistent with that obtained by conventional live NiV test, and gave higher antibody titers than the latter. Additionally, when screening sixty-six fruit bat sera at one dilution, the VSV-NiV-SEAP assay produced identical results to the live NiV test and only required a very small amount (2μl) of sera. The results suggest that this novel VSV-NiV-SEAP assay is safe, useful for high-throughput screening of sera using an ELISA plate reader, and has high sensitivity and specificity.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22115786     DOI: 10.1016/j.jviromet.2011.11.003

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  10 in total

1.  Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting.

Authors:  Jean K Millet; Tiffany Tang; Lakshmi Nathan; Javier A Jaimes; Hung-Lun Hsu; Susan Daniel; Gary R Whittaker
Journal:  J Vis Exp       Date:  2019-03-01       Impact factor: 1.355

2.  Nipah virus infection: current scenario.

Authors:  D D Kulkarni; C Tosh; G Venkatesh; D Senthil Kumar
Journal:  Indian J Virol       Date:  2013-11-07

3.  Outbreak of henipavirus infection, Philippines, 2014.

Authors:  Paola Katrina G Ching; Vikki Carr de los Reyes; Maria Nemia Sucaldito; Enrique Tayag; Alah Baby Columna-Vingno; Fedelino F Malbas; Gilbert C Bolo; James J Sejvar; Debbie Eagles; Geoffrey Playford; Erica Dueger; Yoshihiro Kaku; Shigeru Morikawa; Makoto Kuroda; Glenn A Marsh; Sam McCullough; A Ruth Foxwell
Journal:  Emerg Infect Dis       Date:  2015-02       Impact factor: 6.883

4.  Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.

Authors:  Danielle E Anderson; Chee Wah Tan; Wan Ni Chia; Barnaby E Young; Martin Linster; JennyG H Low; Yee-Joo Tan; Mark I-C Chen; Gavin J D Smith; Yee Sin Leo; David C Lye; Lin-Fa Wang
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

5.  Development and validation of serological assays for viral hemorrhagic fevers and determination of the prevalence of Rift Valley fever in Borno State, Nigeria.

Authors:  David Nadeba Bukbuk; Shuetsu Fukushi; Hideki Tani; Tomoki Yoshikawa; Satoshi Taniguchi; Koichiro Iha; Aiko Fukuma; Masayuki Shimojima; Shigeru Morikawa; Masayuki Saijo; Francis Kasolo; Saka Saheed Baba
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-10-24       Impact factor: 2.184

Review 6.  Henipavirus Encephalitis: Recent Developments and Advances.

Authors:  Kien Chai Ong; Kum Thong Wong
Journal:  Brain Pathol       Date:  2015-09       Impact factor: 6.508

7.  Effective inactivation of Nipah virus in serum samples for safe processing in low-containment laboratories.

Authors:  Shumpei Watanabe; Shuetsu Fukushi; Toshihiko Harada; Masayuki Shimojima; Tomoki Yoshikawa; Takeshi Kurosu; Yoshihiro Kaku; Shigeru Morikawa; Masayuki Saijo
Journal:  Virol J       Date:  2020-10-09       Impact factor: 4.099

Review 8.  Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019.

Authors:  Marcela Salazar-García; Samyr Acosta-Contreras; Griselda Rodríguez-Martínez; Armando Cruz-Rangel; Alejandro Flores-Alanis; Genaro Patiño-López; Victor M Luna-Pineda
Journal:  Front Microbiol       Date:  2022-01-14       Impact factor: 5.640

Review 9.  Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers.

Authors:  Shuetsu Fukushi; Hideki Tani; Tomoki Yoshikawa; Masayuki Saijo; Shigeru Morikawa
Journal:  Viruses       Date:  2012-10-12       Impact factor: 5.048

Review 10.  Current status on the development of pseudoviruses for enveloped viruses.

Authors:  Qianqian Li; Qiang Liu; Weijin Huang; Xuguang Li; Youchun Wang
Journal:  Rev Med Virol       Date:  2017-12-07       Impact factor: 6.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.